A Duke-led collaboration will perform molecular profiling of tissue and blood from Duke biobanks, linking molecular data with clinical records to train models for early disease detection, therapy matching, and new drug target discovery.

Data generated will be shared back with Duke biobanks to fuel ongoing academic research, while strictly adhering to data privacy, security requirements and the terms of the agreement.

Duke biobanks will supply disease-specific cohorts, while Network Bio will conduct sequencing to create large-scale molecular datasets tied to outcomes, with data backflow to Duke for continued research.

Key participants quoted include Asad Ali Ahmad (Network Bio CEO), Svati H. Shah (Duke University School of Medicine), and Raphael Potter (Network Bio Co-Founder and Chief Business Officer).

Raphael Potter of Network Bio stresses the opportunity to test targets, biomarkers, and patient selection against real human outcomes before clinical deployment.

The press release provides media contact details and cites Business Wire as the source.

Asad Ali Ahmad emphasizes that having tissue, blood, and patient outcomes is essential to train AI models that reflect real human disease and treatment trajectories.

Network Bio aims to build a patient world model of disease with applications in precision diagnostics, biomarker discovery, and drug development, based in Palo Alto.

The company’s mission centers on precision diagnostics, biomarker discovery, and drug development through patient-centered data models.

Network Bio situates its work in Palo Alto and frames it as enabling precision diagnostics, biomarker discovery, and drug development via patient-centered data models.

The initiative seeks to identify biomarkers, patient subgroups, and therapeutic targets more quickly to accelerate clinical validation.

Researchers will gain access to advanced molecular profiling and sequencing, reducing costs typically borne by academic researchers.